The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.
Analia Azaro
No relevant relationships to disclose
José Baselga
No relevant relationships to disclose
Juan Manuel SepĂșlveda
No relevant relationships to disclose
Joan Seoane
Consultant or Advisory Role - Lilly
Jordi Rodon Ahnert
Consultant or Advisory Role - Lilly
Irene Brana
No relevant relationships to disclose
Ivelina Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sada Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Luis Paz-Ares
Consultant or Advisory Role - Bayer; Lilly; Pfizer; Roche
Honoraria - Bayer; Lilly; Pfizer; Roche
Matthias Holdhoff
No relevant relationships to disclose
Jaishri O'Neill Blakeley
No relevant relationships to disclose
Michael Anthony Carducci
Research Funding - Lilly